Lilly partners with Amgen for manufacturing potential Covid-19 drugs
Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval
FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US, May 18, 2018. REUTERS/Brendan McDermid
Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental Covid-19 antibody treatments.
Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval, the companies said in a statement.
Keep updated, follow The Business Standard's Google news channel
